News | November 05, 2006

Barnes-Jewish Hospital Poised for CardioWest Implantation

Washington University surgeons at Barnes-Jewish Hospital, St. Louis, began training at UMC in Tucson on Nov. 2 to become one of only nine hospitals in the U.S. certified to implant the CardioWest temporary Total Artificial Heart (TAH-t). Ranked No. 10 on the “U.S. News and World Report’s” Best Heart Hospitals of 2006, the Barnes-Jewish program has earned a reputation for taking on the most challenging cases, including patients who may have been turned down at other implant centers.

The heart transplant team, led by Dr. Nader Moazami, will be the first in the St. Louis area to be certified to implant the TAH-t, a modern version of the Jarvik-7 Artificial Heart.

The program is known as one of the leading centers in the country for post-transplant care and use of cardiac assist devices.

“We know that it (TAH-t) salvages a large number of patients who are really spiraling downward so rapidly that there’s no other device that can bring them back and this device (the TAH-t) does it,” said Dr. Jack Copeland, who has been a leader in artificial heart surgery since 1985.
The CardioWest TAH-t replaces the patient's dying heart. In most patients it is able to restore cardiac output. This facilitates recovery of vital organs, such as the liver and kidneys that have declined because of low blood flow. This improves the condition of patients who were near death from end stage biventricular heart failure. The TAH-t makes them better able to survive a heart transplant.”

Related Content

Xarelto Significantly Reduces Major Cardioavascular Events in Stable CAD and PAD Patients
News | Pharmaceuticals| October 18, 2017
October 18, 2017 — Results from the pivotal Phase 3 COMPASS study found that the...
News | Pharmaceuticals| October 04, 2017
October 4, 2017 — MyoKardia Inc.
Heart Failure Market to Surpass $16 Billion by 2026
News | Heart Failure| September 19, 2017
The heart failure space across the seven key markets of the U.S., France, Germany, Italy, Spain, the U.K. and Japan is...
News | Pharmaceuticals| September 12, 2017
September 12, 2017 — Inclisiran lowers low-density lipoprotein (LDL, or “bad”) cholesterol for up to one year in pati
New FOURIER Analysis Examines How Low Cholesterol Can Safely Go
News | ESC| September 12, 2017
September 12, 2017 — Very aggressive reduction of LDL-cholesterol to ultra-low levels was associated with progressive
CANTOS Study Shows Reducing Inflammation Cuts Cardiovascular Disease, Lung Cancer Risk
News | ESC| September 12, 2017
September 12, 2017 — The IL-1β inhibitor canakinumab lowers the risk of cardiovascular disease and lung cancer risk b
COMPASS Trial Shows Rivaroxaban With Aspirin Improves Stable Cardiovascular Disease
Feature | Antiplatelet and Anticoagulation Therapies| September 12, 2017
September 12, 2017 — Rivaroxaban plus aspirin improves survival and reduces stroke and heart attack in patients with
Merck Announces Results of REVEAL Outcomes Study of Anacetrapib
News | Pharmaceuticals| September 11, 2017
Merck and researchers in the Clinical Trial Service Unit at the University of Oxford announced the publication and...
Real-World Analysis Compares Safety, Effectiveness of Apixaban Versus Warfarin
News | Antiplatelet and Anticoagulation Therapies| August 28, 2017
August 28, 2017 — Bristol-Myers Squibb Company and Pfizer Inc.
Medtronic Announces Global Resolute Onyx DES One-Month DAPT Study
News | Antiplatelet and Anticoagulation Therapies| August 18, 2017
Medtronic plc announced a global randomized clinical trial that will evaluate one-month dual antiplatelet therapy (DAPT...
Overlay Init